In Oct 2007, the FDA declared which the labeling for all PDE5 inhibitors, which include tadalafil, needs a additional prominent warning with the likely possibility of unexpected hearing reduction as the result of submit-promoting stories of short-term deafness associated with usage of PDE5 inhibitor